Tech Company Financing Transactions
Endevica Bio Funding Round
Private investors participated in a $10 million Series B capital raise for Endevica Bio. The round was recorded on 1/19/2023.
Transaction Overview
Company Name
Announced On
1/19/2023
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds for continuing the research and development of TCMBO7, its melanocortin-3/4 antagonist peptide candidate, for the treatment of cachexia, as well as for working capital or other general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1945 Techny Rd 14
Northbrook, IL 60062
USA
Northbrook, IL 60062
USA
Phone
Website
Email Address
Overview
Endevica Bio's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. The company was formed in 2009 to create best in class peptide drug candidates with better safety and efficacy properties than other drugs in the same class.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Russell Potterfield
Chief Medical Officer
Daniel Marks
Chief Scientific Officer
Kenneth Gruber
Browse more venture capital transactions:
Prev: 1/19/2023: Koinos Group venture capital transaction
Next: 1/19/2023: Scrintal venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. VC transactions reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs